Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Radiation Fibrosis Syndrome 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Adenocarcinoma 1Inflammation 1Fibrosis 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Camurati-Engelmann Syndrome 1

Interventions

Paclitaxel 10Carboplatin 6Bevacizumab 5liposomal doxorubicin 4Topotecan 3Cyclophosphamide 3pembrolizumab 2oregovomab 2olaparib 2niraparib 2fludarabine 2Nivolumab 2Drug Therapy 2trastuzumab deruxtecan 1rucaparib 1ribociclib 1palbociclib 1mirvetuximab soravtansine 1isoquercitrin 1irinotecan sucrosofate 1fludarabine phosphate 1denileukin diftitox 1anlotinib 1Tinzaparin 1Saline Solution 1Propranolol 1Preoperative Exercise 1Platinum 1Palliative Care 1Neoadjuvant Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × Losartan × 90 days × Clear all
NCT07265739 2026-05-06

Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer

Massachusetts General Hospital

Phase 2 Not yet recruiting
27 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡